TD Cowen analyst Marc Frahm downgraded Elevation Oncology (NASDAQ: ELEV) from Buy to Hold.The analyst comments "We view Elevation's planned ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE